Relationships between HMG-CoA reductase inhibitors (statin) use and strength, balance and falls in older people

Internal Medicine Journal

Volumn 42, Issue 12, 2012, Pages 1329-1334

  Haerer, W ^a   Delbaere, K ^b   Bartlett, H ^c   Lord, S R ^b   Rowland, J ^d  

^a RMIT UNIVERSITY   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

^d THE PRINCE CHARLES HOSPITAL   (Australia)

Author keywords

Accidental fall; Balance; Muscle strength; Statin

Indexed keywords

ATORVASTATIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ADULT; AGED; ARTICLE; BALANCE DISORDER; BODY EQUILIBRIUM; COMMUNITY LIVING; FALLING; FEMALE; FOLLOW UP; FUNCTIONAL STATUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MOVEMENT (PHYSIOLOGY); MUSCLE STRENGTH; MUSCLE WEAKNESS; PRIORITY JOURNAL; QUADRICEPS FEMORIS MUSCLE; SIDE EFFECT; WALKING SPEED;

ACCIDENTAL FALLS; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LOWER EXTREMITY; MALE; MUSCLE STRENGTH; POSTURAL BALANCE;

EID: 84871376902     PISSN: 14440903     EISSN: 14455994     Source Type: Journal    
DOI: 10.1111/j.1445-5994.2011.02622.x     Document Type: Article

References (49)

1. Brunton L, Lazo J, Parker K. Goodman and Gilman's The Pharmacological Basis of Therapeutics. New York: McGraw-Hill; 2006.
2. MacDonald JS, Halleck MM. The toxicology of HMG-CoA reductase inhibitors: prediction of human risk. Toxicol Pathol 2004; 32: 26-41.
3. Pedersen T, Kjekshus J, Berg K, Haghfelt T, Faergeman O, Thorgiersson E etal. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-1989.
4. Tobert JA. Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors. Nat Rev Drug Discov 2003; 2: 517-526.
5. Nicholls S, Tuzeu E, Sipahi I, Grasso A, Schoenhagen P, Ho T etal. Statins, high-density lipoprotein cholesterol and regression of coronary atherosclerosis. J Am Med Assoc 2007; 297: 499-508.
6. Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90056 participants in 14 randomised trials of statins. Lancet 2005; 366: 1267-1278.
7. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R etal. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350: 1495-1505.
8. Dobkin BH. Underappreciated statin-induced myopathic weakness causes disability. Neurorehabil Neural Repair 2005; 19: 259-263.
9. Mohaupt MG, Karas RH, Babiychuk EB, Sanchez-Freire V, Monastyrskaya K, Iyer L etal. Association between statin-associated myopathy and skeletal muscle damage. Can Med Assoc J 2009; 181: E11-18.
10. Pasternak RC, Smith SC, Bairey-Merz N, Grundy SM, Cleeman JI, Lenfant C. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. J Am Coll Cardiol 2002; 40: 567-572.
11. Phillips PS, Hass RH, Bannykh S, Hathaway S, Gray NL, Kimura BJ etal. Statin-associated myopathy with normal creatine kinase levels. Ann Intern Med 2002; 137: 581-585.
12. Flint O, Masters B, Gregg R, Durham S. Inhibition of cholesterol synthesis by squalene synthase inhibitors does not induce myotoxicity in vitro. Toxicol Appl Pharmacol 1997; 145: 91-98.
13. Thompson P, Clarkson P, Karas R. Statin-associated myopathy. J Am Med Assoc 2003; 289: 1681-1690.
14. Chapman JM, Carrie A. Mechanisms of statin-induced myopathy: a role for the ubiquitin-proteasome pathway? Arterioscler Thromb Vasc Biol 2005; 25: 2441-2444.
15. Urso ML, Clarkson PM, Hittel D, Hoffman EP, Thompson PD. Changes in ubiquitin proteasome pathway gene expression in skeletal muscle with exercise and statins. Arterioscler Thromb Vasc Biol 2005; 25: 2560-2566.
16. Ballantyne CM, Corsin A, Davidson MH, Holdaas H, Jacobson TA, Leitersdorf E etal. Risk for myopathy with statin therapy in high risk patients. Arch Intern Med 2003; 163: 553-564.
17. Bellosta S, Paoletti R, Corsini A. Safety of statins: focus on clinical pharmacokinetics and drug interactions. Circulation 2004; 109: 50-57.
18. Koski K, Luukinen H, Laippala P, Kivela S. Physiological factors and medications as predictors of injurious falls by elderly people: a prospective population-based study. Age Ageing 1996; 25: 29-38.
19. Nevitt M, Cummings S, Kidd S, Black D. Risk factors for recurrent nonsyncopal falls. J Am Med Assoc 1989; 261: 2663-2668.
20. Sathasivam S, Lecky B. Statin induced myopathy. Br Med J 2008; 337: 1159-1162.
21. Tinetti M, Baker D, McAvay G, Claus EB, Garrett P, Gattschalk M etal. A multifactrial intervention to reduce the risk of falling among elderly people living in the community. N Engl J Med 1994; 331: 821-827.
22. Tinetti M, Speechley M, Ginter S. Risk factors for falls among elderly persons living in the community. N Engl J Med 1988; 319: 1701-1706.
23. Tomlinson SS, Mangione KK. Potential adverse effects of statins on muscle. Phys Ther 2005; 85: 459-465.
24. Scott D, Blizzard L, Fell J, Jones G. Statin therapy, muscle function and falls risk in community-dwelling older adults. QJM 2009; 102: 625-633.
25. Agostini J, Tinetti M, Han L, McAvay G, Foody J, Concato J. Effects of statin use on muscle strength, cognition and depressive symptoms in older adults. J Am Geriatr Soc 2007; 55: 420-425.
26. McDermott M, Guralnik J, Greenland P, Pearce WH, Criqui MH, Liu K etal. Statin use and leg functioning in patients with and without lower extremity peripheral arterial disease. Circulation 2003; 107: 757-761.
27. Giri J, McDermott M, Greenland P, Guralnik JM, Criqui MH, Liu K etal. Statin use and functional declin ein patients with and without peripheral arterial disease. J Am Coll Cardiol 2006; 47: 998-1004.
28. Ashfield T, Syddall H, Martin H, Dennison E, Cooper C, Aihie Sayer A. Grip strength and cardiovascular drug use in older people: findings from the Herfordshire Cohort Study. Age Ageing 2010; 39: 185-191.
29. Kochan N, Broday H, Trollor J, Draper B, Wen W, Slavin M etal. The Sydney Memory and Ageing Study (MAS): a Population-Based Longitudinal Investigation of Cognitive Health in the Elderly. Sydney. New South Wales: University of New South Wales; 2005.
30. Delbaere K, Close J, Heim J, Sachdev PS, Brodaty H, Slavin MJ etal. A multifactorial approach to understanding fall risk in older people. J Am Geriatr Soc 2010; 58: 1679-1985.
31. Lord S, Menz H, Tiedermann A. A physiological profile approach to falls risk assessment and prevention. Phys Ther 2003; 83: 237-252.
32. Lord S, Sherrington C, Menz H, Close J. Falls in Older People. Cambridge: University Press; 2008.
33. Whitney J, Lord S, Close J. Streamlining assessment and intervention in a falls clinic using the timed up and go test and physiolocial profile assessments. Age Ageing 2005; 34: 567-571.
34. Lord S, Ward J, Williams P. Exercise effect on dynamic stability in older women: a randomized controlled trial. Arch Phys Med Rehabil 1996; 77: 232-236.
35. Lord S, Murray S, Chapman K, Munro B, Tiedemann A. Sit-to-stand performance depends on sensation, speed, balance and psychological status in addition to strength in older people. J Gerontol A Biol Sci Med Sci 2002; 57: M539-543.
36. Lord S, Tiedemann A, Chapman K, Munro B, Murray S, Sherrington C. The effect of an individualized fall prevention program on fall risk and falls in older people: a randomized, controlled trial. J Am Geriatr Soc 2005; 53: 1296-1304.
37. Tiedemann A, Shmada H, Sherrington C, Murray S, Lord S. The comparative ability of eight functional mobility tests for predicting falls in community-dwelling older people. Age Ageing 2008; 37: 430-435.
38. Hauer K, Lamb S, Jorstad E, Todd C, Becker C. Systematic review of definitions and methods of measuring falls in randomised controlled fall prevention trials. Age Ageing 2006; 35: 5-10.
39. Bland J, Altman D. Statistics notes: transforming data. Br Med J 1996; 312: 770.
40. Tabachnick B, Fidell L. Using Multivariate Statistics. Sydney: HarperCollins; 1996.
41. Menz H, Lord S. Foot and ankle characteristics associated with impaired balance and functional ability in older people. J Gerontol 2005; 60: 1546-1552.
42. Duncan P, Weiner D, Chandler J, Studenski S. Functional reach: a new clinical measure of balance. J Gerontol 1990; 45: M192-197.
43. Hageman P, Leibowitz J, Blanke D. Age and gender effects on postural control measures. Arch Phys Med Rehabil 1995; 76: 961-965.
44. Weiner D, Duncan P, Chandler J, Studenski S. Functional reach: a marker of physical frailty. J Am Geriatr Soc 1992; 40: 203-207.
45. Duncan P, Studenski S, Chandler J, Prescott B. Functional reach: predictive validity in a sample of elderly male veterans. J Gerontol 1992; 47: M93-98.
46. Lord S, Lloyd D, Sek K. Sensori-motor function, gait patterns and falls in community-dwelling women. Age Ageing 1996; 25: 292-299.
47. Maki B, Holliday P, Topper A. A Prospective study of postural balance and risk of falling in an ambulatory and independent elderly population. J Gerontol 1994; 49: M72-83.
48. Miller S. Emerging mechanisms for secondary cardioprotective effects of statins. Cardiovasc Res 2001; 52: 5-7.
49. Scalia R, Gooszen M, Jones S, Hoffmeyer M, Rimmer DM, Trocha SD etal. Simvastatin exerts both anti-inflammatory and cardioprotective effects in apolipoprotein e-deficient mice. Circulation 2001; 103: 2598-2603.